Autoimmune adrenal insufficiency: recognition and management.
Level 5 - mechanism / opinion, no new human data
Narrative review and clinical guidance with no primary empirical human data reported.
PubMed 18034517 · doi:10.2165/00063030-200013020-00004
What was done
This narrative clinical review outlines the pathophysiology, diagnostic criteria, and management strategies for autoimmune Addison's disease. No primary experimental trial, cohort data, or systematic search methodology is described in the abstract.
What was found
The abstract provides descriptive clinical guidance without quantitative trial results. It describes autoimmune adrenal cortex destruction mediated by autoreactive immune cells against 21-hydroxylase. Key clinical features include fatigue, weight loss, anorexia, salt craving, hypotension, hyperpigmentation, hyperkalemia, hyponatremia, and low basal or ACTH-stimulated cortisol. It reports that 21-hydroxylase autoantibody testing enables detection prior to complete gland destruction. Recommended treatment includes 100 mg intravenous hydrocortisone plus saline for acute adrenocortical crisis without waiting for lab results, followed by divided, lower-dose glucocorticoid and mineralocorticoid maintenance therapy. No specific statistical metrics or numerical outcome data are presented.
Why it matters
It provides a concise clinical summary of 21-hydroxylase antibody testing for early diagnosis of Addison's disease and outlines standard emergency and maintenance hormone replacement regimens.
Limits
The abstract contains no original data, sample size, or systematic methodology. Diagnostic accuracy metrics (sensitivity, specificity) for autoantibody assays and empirical comparative evidence for specific steroid dosing regimens are not provided.
Cited by
- context Addison's disease is an autoimmune condition characterized by low cortisol, weight loss, skin hyperpigmentation, poor immune function, and inability to retain sodium.